It's currently dominated by a few big names in Eli Lilly and Novo Nordisk, but that can change drastically in the future. The ...

But that's about to change, as weight-loss treatments will soon be available in pill form. RELATED: What Really Happens If ...

The study concentrates on the FDA-approved injectable medications semaglutide and liraglutide. A study conducted by the ...

Among patients receiving persistent medication at one year, 61% of patients prescribed semaglutide for obesity achieved at ...

Most trillion-dollar companies today are in the technology sector, but one particular healthcare stock is knocking on the ...

As Novo Nordisk A/S and Eli Lilly and Co. go head-to-head in the U.S. and Chinese glucagon-like peptide-1 receptor agonists ...

Chinese pharmaceutical and biotech companies are leading development of glucagon-like peptide-1 receptor agonists as Novo Nordisk A/S and Eli Lilly and Co. edge closer to launching blockbuster ...

French researchers have developed a new drug delivery system that could cut the dosing schedule for the type 2 diabetes and ...

GLP-1RA vs insulin use was associated with improved cardiovascular and kidney outcomes among patients with type 2 diabetes on dialysis.

to examine potential applications of glucagon-like peptide-1 receptor (GLP-1R) agonists in central nervous system disorders, such as dementia, Parkinson’s disease, substance and alcohol use disorders, ...

The National Academies of Sciences, Engineering, and Medicine are private, nonprofit institutions that provide expert advice on some of the most pressing challenges facing the nation and world. Our ...